Skip to main content
. Author manuscript; available in PMC: 2019 Jul 17.
Published in final edited form as: Circulation. 2018 Feb 5;138(3):287–304. doi: 10.1161/CIRCULATIONAHA.117.031258

Fig. 1. Pathological upregulation of MiD49 and MiD51 in human and experimental PAH.

Fig. 1

Fig. 1

(A) Representative immunoblots and densitometry demonstrating increased protein expression of MiD49 and MiD51 in human PAH PASMC (n=6) vs normal human PASMC (n=3). β-actin was used as the loading control (*P < 0.05).

(B) Confocal images showing higher expression of MiD49 and MiD51 in PAH PASMC. STED super-resolution images showing association of MiDs with mitochondria and Drp1. Staining used in the images to create colors: mitochondria (red, MitoTracker™ Deep Red), MiD49, MiD51 (green) and Drp1 (cyan) in normal and PAH PASMC. Scale bar: 10 μm for the confocal images and 1 μm for the STED images.

(C) Representative images and quantification of immunohistochemistry demonstrating increased expression of MiD49 and MiD51 protein (brown) in the media and intima of small pulmonary arteries from human PAH lungs vs control lungs. 11–14 distal pulmonary arteries, <200μm in diameter from 6 subjects per group (***P < 0.001; n=11–14/subject). Scale bar: 25 μm.

(D) Representative images and quantification of immunohistochemistry demonstrating increased expression of MiD49 and MiD51 (brown) in the media and intima of distal pulmonary arteries from MCT PAH rats. 8–14 distal pulmonary arteries, <150 μm in diameter from 5 animals per group (***P < 0.001). Scale bar: 25 μm.